Özen, AlaattinFayda, Merdan2022-06-162022-06-162022Özen, A., & Fayda, M. (2022). Cardiotoxicity after the lymphoma. Turk Onkoloji Dergisi, 37(2), 44-50. doi:10.5505/tjo.2022.S10071300-7467https://doi.org/10.5505/tjo.2022.S1007https://hdl.handle.net/20.500.12713/2914SUMMARY Radiotherapy (RT) is the cornerstone component of the current successful treatment of Hodgkin lymphoma (HL). Although RT has been used alone to cure in most patients in decades, combined modality regimes are preferred in most HL patients currently, besides early-stage lymphocyte predominance HL and for selected patients with classical HL who have contraindications to chemotherapy. Although clas-sic RT fields, doses, and techniques have fundamentally changed over the years, the heart is still an organ at risk, and patients with radiation-induced cardiovascular complications are increased in the long term. In this paper, we aimed to review literature about radiation-induced cardiotoxicity in lymphoma patients treated with mediastinal RT. © 2022.eninfo:eu-repo/semantics/openAccessCardiotoxicityHodgkin Lymphoma (HL)RadiotherapyReview Article3724450WOS:0011325824000072-s2.0-85127663439N/A10.5505/tjo.2022.S1007Q4